Free for academic non-profit institutions. Other users need a Commercial license
The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. [provided by RefSeq, Jul 2008]
FGF2 (Fibroblast Growth Factor 2) is a Protein Coding gene. Diseases associated with FGF2 include Corneal Neovascularization and Chronic Ulcer Of Skin. Among its related pathways are RET signaling and Signaling by FGFR2 in disease. Gene Ontology (GO) annotations related to this gene include cytokine activity and heparin binding. An important paralog of this gene is FGF1.
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005104 | fibroblast growth factor receptor binding | IPI | 2161540 |
GO:0005125 | cytokine activity | IDA | 18059339 |
GO:0005178 | integrin binding | IDA | 28302677 |
GO:0005515 | protein binding | IPI | 9700203 |
GO:0008083 | growth factor activity | IDA | 18059339 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005576 | extracellular region | TAS | -- |
GO:0005615 | extracellular space | IDA | 2161540 |
GO:0005623 | cell | IEA | -- |
GO:0005634 | nucleus | IEA | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | RET signaling |
.92
|
.92
|
2 | Downstream signaling of activated FGFR2 | ||
3 | Apoptotic Pathways in Synovial Fibroblasts |
Cellular Apoptosis Pathway
.85
Mitochondrial Apoptosis
.85
Apoptotic Pathways in Synovial Fibroblasts
.84
p53 Mediated Apoptosis
.84
DHA Signaling
.74
Telomerase Components in Cell Signaling
.72
PPAR Pathway
.66
|
Rac1 Pathway
.65
Glioma Invasiveness
.64
Actin-Based Motility by Rho Family GTPases
.62
ERK5 Signaling
.61
eIF2 Pathway
.60
Rap1 Pathway
.57
Nuclear Receptor Activation by Vitamin-A
.57
|
4 | Negative regulation of FGFR3 signaling | ||
5 | GPCR Pathway |
Paxillin Interactions
.73
Ras Pathway
.73
GPCR Pathway
.62
Pancreatic Adenocarcinoma
.59
|
Breast Cancer Regulation by Stathmin1
.58
NFAT in Immune Response
.58
Estrogen Pathway
.55
P2Y Receptor Signaling
.38
|
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000165 | MAPK cascade | TAS | -- |
GO:0000187 | activation of MAPK activity | TAS | 9712850 |
GO:0001525 | angiogenesis | IEA | -- |
GO:0001658 | branching involved in ureteric bud morphogenesis | IDA | 12631064 |
GO:0001938 | positive regulation of endothelial cell proliferation | IDA,IMP | 18059339 |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
Pentosan Polysulfate | Approved | Pharma | Target, antagonist, inhibitor | 0 | ||
Sirolimus | Approved, Investigational | Pharma | Target, other/unknown, inhibitor | Kinase Inhibitors, Mammalian target of rapamycin (mTOR) inhibitors | 1377 | |
Heparin | Approved, Investigational | Pharma | Antagonist, Target | 1058 | ||
Sucralfate | Approved | Pharma | Target, agonist, inducer | 15 | ||
Thalidomide | Approved, Investigational, Withdrawn | Pharma | Immunomodulatory agent,sedative drug,angiogenesis inhibitor, TNF-alpha synthesis inhibitor, Immunomodulatory agents | 429 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs |
---|